Medicaid Provider SpendingClaims paid 2018–2024 · HHS public file
Home › NC › Burlington › NPI 1104829159
Lab

Laboratory Corporation of America

Laboratory Corporation of America was paid $59.75M by Medicaid between Jan 2018 and Dec 2024, across 490 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 8.5% of everything it billed.

33Billing provider infoLABORATORY CORPORATION OF AMERICA
BURLINGTON, NC 27215
33aNPI1104829159assigned 05/23/2005
33bProvider typeClinical Medical Laboratory
28Total paid$59.75M
24GClaims15,294,807
24DCodes billed490
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers

Next to other Clinical Medical Laboratory providers in North Carolina

Rank by total paid#6 of 128
Median peer was paid$268K
This provider vs. median223×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Auditor's notes

Automated statistical signals. Not evidence of fraud — how these are computed.

Entity ProliferationAuthorized official WILLIAMS, KIMBERLY controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service

Paid by month

$0$500K$1.0M$1.5M2018201920202021202220232024
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
YearClaimsPaid
20181,989,689$9.69M
20192,350,649$8.29M
20201,804,929$8.89M
20212,416,016$11.45M
20222,198,748$8.52M
20232,605,824$8.51M
2024incomplete1,928,952$4.39M
Box 24 · Service lines

What it billed for

CodeServiceShareClaimsBene. recordsPaid
U0003 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r 8.5% 138,784 124,086 $5.06M
88305 Level IV - Surgical pathology, gross and microscopic examination 4.9% 76,918 74,983 $2.91M
84443 Thyroid stimulating hormone (TSH) 4.5% 829,966 813,015 $2.69M
80053 Comprehensive metabolic panel 4.5% 1,207,124 1,157,205 $2.66M
87491 Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe 4.4% 361,193 348,670 $2.63M
82306 Vitamin D; 25 hydroxy, includes fraction(s), if performed 4.4% 478,297 470,549 $2.63M
80061 Lipid panel 4.4% 984,102 966,487 $2.60M
87591 Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe 4.3% 363,058 350,466 $2.60M
85025 Blood count; complete (CBC), automated, and automated differential WBC count 3.1% 1,133,124 1,078,892 $1.85M
81220 CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants 3.0% 8,696 8,521 $1.80M
81420 Fetal chromosomal aneuploidy genomic sequence analysis panel 3.0% 5,920 5,889 $1.77M
83036 Hemoglobin; glycosylated (A1C) 2.6% 836,344 821,118 $1.58M
478 more codes
87798 Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism 2.4% 79,743 $1.45M
87624 Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types 1.7% 121,618 $1.00M
87389 Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies 1.6% 208,440 $971K
87661 Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe 1.6% 110,791 $966K
88175 Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer 1.5% 158,792 $922K
86003 1.5% 33,297 $898K
87801 Infectious agent detection by nucleic acid; amplified probe, multiple organisms 1.0% 55,415 $622K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay <1% 48,394 $525K
80074 <1% 54,672 $520K
87086 Culture, bacterial; quantitative colony count, urine <1% 259,415 $486K
84439 <1% 280,474 $451K
84153 <1% 109,579 $444K
86803 <1% 137,748 $438K
U0005 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 <1% 42,529 $418K
82607 <1% 159,526 $418K
86235 <1% 16,736 $416K
36415 Collection of venous blood by venipuncture <1% 1,057,253 $409K
82274 <1% 97,820 $403K
88312 <1% 14,296 $395K
86480 <1% 44,162 $388K
82746 <1% 130,926 $384K
80050 General health panel <1% 22,703 $370K
84403 <1% 59,655 $359K
83013 <1% 25,089 $323K
82043 <1% 204,546 $298K
83970 <1% 24,377 $293K
82728 <1% 104,748 $289K
87536 <1% 10,089 $286K
88313 <1% 8,641 $284K
80081 <1% 6,445 $271K
88341 <1% 3,457 $271K
81257 <1% 571 $265K
82570 <1% 173,779 $256K
80048 Basic metabolic panel (calcium, ionized) <1% 95,464 $250K
87186 <1% 96,119 $240K
86769 <1% 9,565 $238K
87522 Neg quan hep c or qual rna <1% 12,146 $230K
88342 <1% 5,978 $213K
83550 <1% 111,016 $201K
86592 <1% 213,020 $198K
87902 <1% 1,576 $198K
82670 <1% 33,542 $194K
87088 <1% 100,918 $190K
81329 <1% 3,478 $188K
87340 <1% 100,325 $179K
84481 <1% 51,699 $173K
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed <1% 4,059 $173K
84402 <1% 26,791 $168K
83540 <1% 123,000 $167K
87517 <1% 8,137 $161K
88142 <1% 21,898 $160K
85027 <1% 121,356 $158K
86038 <1% 59,571 $158K
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed <1% 1,446 $146K
83880 <1% 11,740 $144K
81001 <1% 230,550 $143K
84436 <1% 101,268 $136K
87070 <1% 55,635 $136K
83001 <1% 42,179 $135K
81003 <1% 302,283 $131K
86706 <1% 46,939 $125K
84480 <1% 44,073 $125K
82652 <1% 19,759 $123K
81374 <1% 3,411 $116K
88141 <1% 23,923 $114K
83002 <1% 35,798 $109K
86704 <1% 32,666 $105K
86696 <1% 23,105 $104K
87077 <1% 53,578 $100K
87507 <1% 405 $100K
86376 <1% 30,697 $97K
86140 <1% 83,374 $95K
84702 <1% 45,013 $94K
84550 <1% 111,176 $93K
84146 <1% 29,000 $92K
82105 <1% 21,924 $92K
83735 <1% 56,265 $91K
86708 <1% 21,673 $86K
80076 <1% 53,797 $83K
83516 <1% 14,785 $82K
87637 Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV <1% 1,894 $79K
82785 <1% 24,255 $77K
86360 <1% 5,141 $77K
87481 <1% 2,859 $77K
87529 <1% 6,426 $76K
82378 <1% 19,963 $75K
86762 <1% 41,435 $73K
99199 Unlisted special service, procedure or report <1% 13,345 $73K
84479 <1% 61,315 $73K
84144 <1% 19,114 $72K
88304 <1% 5,209 $70K
83655 <1% 34,846 $70K
85610 <1% 75,193 $69K
86160 <1% 13,129 $69K
82784 <1% 18,435 $68K
86225 <1% 18,755 $65K
87209 <1% 12,081 $65K
86695 <1% 20,270 $63K
87081 <1% 48,121 $63K
81401 <1% 411 $63K
86300 <1% 10,241 $63K
87150 <1% 13,731 $63K
85730 <1% 47,966 $61K
86431 <1% 50,818 $60K
86800 <1% 16,521 $60K
81251 <1% 187 $59K
85652 <1% 114,651 $58K
84154 <1% 16,272 $57K
86787 <1% 18,387 $57K
82627 <1% 12,757 $55K
86147 <1% 4,201 $54K
84681 <1% 7,759 $52K
86200 <1% 21,909 $51K
82533 <1% 10,681 $50K
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed <1% 983 $46K
86141 <1% 13,766 $42K
86304 <1% 8,882 $41K
86665 <1% 3,705 $41K
83520 <1% 8,543 $41K
86361 <1% 4,608 $40K
87901 <1% 249 $40K
83690 <1% 22,812 $40K
88307 <1% 586 $38K
86635 <1% 3,782 $38K
87900 <1% 510 $38K
88112 <1% 2,012 $38K
88185 <1% 242 $38K
84100 <1% 35,124 $37K
86317 <1% 17,562 $37K
84445 <1% 3,937 $36K
81243 <1% 1,490 $36K
82550 <1% 20,993 $34K
80347 <1% 8,483 $33K
86765 <1% 14,784 $33K
87177 <1% 12,161 $32K
87338 <1% 15,625 $32K
87075 <1% 8,546 $31K
82672 <1% 5,038 $31K
86735 <1% 13,307 $31K
87625 <1% 1,144 $31K
86146 <1% 2,205 $31K
86780 <1% 8,951 $30K
87427 <1% 9,482 $30K
81200 <1% 175 $30K
83615 <1% 25,456 $30K
80361 <1% 11,160 $30K
83525 <1% 13,047 $29K
81330 <1% 175 $29K
88173 <1% 637 $29K
87045 <1% 9,538 $28K
82977 <1% 24,181 $28K
83721 <1% 12,973 $28K
86301 <1% 5,239 $27K
86677 <1% 4,052 $27K
84165 <1% 7,851 $27K
84450 <1% 35,618 $27K
82024 <1% 3,415 $26K
87635 Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe <1% 988 $26K
84156 <1% 28,712 $26K
82565 <1% 32,744 $25K
80365 <1% 10,466 $25K
83090 <1% 5,472 $25K
86850 <1% 31,172 $23K
84460 <1% 26,234 $23K
80164 <1% 6,567 $23K
82140 <1% 4,315 $23K
82951 <1% 13,030 $23K
82150 <1% 17,604 $23K
86334 <1% 3,494 $22K
81162 <1% 12 $22K
84425 <1% 3,724 $21K
83883 <1% 3,612 $21K
80069 <1% 12,563 $21K
82950 <1% 27,174 $21K
80348 <1% 10,771 $20K
82947 <1% 41,090 $20K
80373 <1% 9,985 $20K
87906 <1% 234 $19K
80354 <1% 10,563 $19K
80358 <1% 10,218 $19K
83498 <1% 3,188 $19K
84075 <1% 21,380 $18K
83992 <1% 6,307 $18K
82310 <1% 19,376 $18K
86709 <1% 7,282 $18K
85060 <1% 4,234 $18K
80353 <1% 9,887 $18K
83521 <1% 1,378 $17K
82330 <1% 4,233 $17K
80359 <1% 10,154 $17K
82248 <1% 17,471 $17K
87535 <1% 2,563 $17K
87046 <1% 9,518 $17K
84520 <1% 27,037 $17K
80372 <1% 9,812 $17K
84270 <1% 3,712 $17K
82247 <1% 24,178 $17K
84207 <1% 2,175 $16K
87480 <1% 6,216 $16K
83921 <1% 2,658 $16K
82397 <1% 3,750 $16K
83014 <1% 12,306 $16K
86256 <1% 2,395 $16K
86364 <1% 5,398 $16K
82507 <1% 1,084 $16K
87510 <1% 6,213 $16K
80197 <1% 4,328 $15K
87660 <1% 6,191 $15K
83695 <1% 2,286 $15K
82040 <1% 20,989 $15K
86664 <1% 2,519 $15K
84155 <1% 23,628 $15K
0202U Oncology (prostate), multianalyte, gene expression profiling <1% 45 $15K
84703 <1% 13,184 $15K
83993 <1% 3,294 $14K
85045 <1% 19,983 $13K
81596 <1% 1,196 $13K
80178 <1% 4,707 $13K
86901 <1% 36,479 $13K
86900 <1% 36,520 $13K
86341 <1% 1,285 $13K
87563 <1% 4,275 $13K
87350 <1% 4,318 $12K
82172 <1% 4,134 $12K
83021 <1% 2,180 $12K
87324 <1% 3,167 $12K
86705 <1% 4,641 $11K
84305 <1% 3,262 $11K
80051 <1% 7,068 $11K
86381 <1% 2,449 $11K
86707 <1% 3,874 $11K
84466 <1% 2,535 $11K
87538 <1% 2,196 $10K
86255 <1% 3,713 $10K
84132 <1% 15,632 $10K
84410 <1% 713 $10K
99001 <1% 3,180 $10K
85379 <1% 3,521 $10K
82626 <1% 2,271 $9K
87329 <1% 2,766 $9K
83010 <1% 3,214 $9K
87650 <1% 514 $9K
U0002 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc <1% 176 $9K
86593 <1% 3,472 $9K
84482 <1% 1,668 $9K
86008 <1% 472 $8K
80326 <1% 6,140 $8K
85613 <1% 2,724 $8K
80377 <1% 6,161 $8K
84478 <1% 7,178 $8K
0097U <1% 38 $8K
82390 <1% 3,329 $8K
84295 <1% 14,085 $8K
86359 <1% 1,419 $8K
83945 <1% 1,087 $8K
84166 <1% 1,344 $8K
80364 <1% 6,131 $7K
86037 <1% 1,108 $7K
82668 <1% 1,645 $7K
80341 <1% 6,160 $7K
80337 <1% 6,198 $7K
82088 <1% 757 $7K
82435 <1% 13,580 $7K
80370 <1% 6,216 $7K
87255 <1% 816 $7K
86618 <1% 720 $7K
82103 <1% 2,125 $7K
86258 <1% 2,150 $7K
80366 <1% 6,234 $7K
80367 <1% 6,134 $7K
80331 <1% 6,130 $6K
80355 <1% 6,249 $6K
80368 <1% 6,268 $6K
80360 <1% 6,214 $6K
80338 <1% 6,204 $6K
80371 <1% 6,129 $6K
80334 <1% 6,197 $6K
80357 <1% 6,165 $6K
80344 <1% 6,130 $6K
86015 <1% 2,283 $6K
80324 <1% 3,647 $6K
86694 <1% 2,108 $6K
82465 <1% 9,555 $6K
88344 <1% 16 $6K
80177 <1% 1,541 $6K
83020 <1% 3,628 $6K
84432 <1% 1,282 $6K
86162 <1% 1,503 $6K
82340 <1% 2,018 $5K
80346 <1% 2,192 $5K
85598 <1% 1,144 $5K
80159 <1% 848 $5K
88184 <1% 230 $5K
87101 <1% 2,577 $5K
81025 <1% 4,619 $5K
84630 <1% 2,913 $5K
85732 <1% 2,320 $5K
85018 <1% 15,600 $4K
85014 <1% 11,931 $4K
84300 <1% 1,999 $4K
82525 <1% 1,523 $4K
84484 <1% 682 $4K
87804 Infectious agent antigen detection by immunoassay; Influenza, each type <1% 179 $4K
83704 <1% 438 $4K
86663 <1% 643 $4K
87205 <1% 2,619 $4K
86702 <1% 875 $4K
86060 <1% 2,832 $4K
80185 <1% 626 $4K
88189 <1% 111 $4K
82085 <1% 1,836 $4K
85660 <1% 2,027 $4K
86790 <1% 234 $3K
84560 <1% 1,223 $3K
83003 <1% 137 $3K
82232 <1% 423 $3K
84080 <1% 620 $3K
84105 <1% 1,054 $3K
87502 Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets <1% 181 $3K
86644 <1% 722 $3K
84134 <1% 601 $3K
85240 <1% 788 $3K
82436 <1% 981 $3K
81256 <1% 110 $3K
82747 <1% 780 $3K
88360 <1% 24 $3K
86231 <1% 3,217 $3K
84540 <1% 945 $3K
84133 <1% 1,080 $3K
80299 <1% 440 $3K
82952 <1% 5,672 $3K
89055 <1% 1,775 $3K
84244 <1% 610 $3K
81241 <1% 218 $3K
85246 <1% 619 $3K
84392 <1% 987 $3K
85041 <1% 6,546 $2K
85670 <1% 1,738 $2K
84378 <1% 2,607 $2K
86331 <1% 789 $2K
87206 <1% 1,377 $2K
80156 <1% 430 $2K
87521 Neg quan hep c or qual rna <1% 499 $2K
82615 <1% 474 $2K
86308 <1% 1,379 $2K
G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed <1% 38 $2K
86005 <1% 1,360 $2K
80055 <1% 185 $2K
85048 <1% 6,594 $2K
86701 <1% 595 $2K
85007 <1% 2,670 $2K
87636 Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B <1% 196 $2K
82653 <1% 502 $2K
81206 <1% 47 $2K
81490 <1% 58 $2K
83935 <1% 830 $2K
87799 <1% 125 $2K
81270 <1% 65 $2K
87076 <1% 594 $2K
81207 <1% 46 $1K
85245 <1% 426 $1K
81050 <1% 914 $1K
86171 <1% 1,208 $1K
82239 <1% 527 $1K
80175 <1% 485 $1K
83986 <1% 956 $1K
83835 <1% 304 $1K
82166 <1% 584 $1K
87210 <1% 685 $1K
82575 <1% 722 $1K
83519 <1% 129 $1K
86645 <1% 263 $1K
86335 <1% 99 $1K
82107 <1% 206 $1K
86692 <1% 83 $960.00
82553 <1% 235 $959.32
87493 <1% 144 $923.97
82679 <1% 129 $899.98
82365 <1% 170 $885.81
82787 <1% 82 $878.21
87040 <1% 189 $854.05
85705 <1% 145 $839.39
82610 <1% 527 $826.85
85306 <1% 200 $792.85
82374 <1% 1,041 $774.32
82157 <1% 225 $722.65
84590 <1% 362 $678.51
86671 <1% 355 $636.14
86357 <1% 337 $628.27
81422 <1% 774 $600.00
80356 <1% 238 $591.05
86777 <1% 135 $587.40
87106 <1% 122 $560.84
88302 <1% 37 $520.49
80202 <1% 72 $520.02
82542 <1% 130 $500.37
86337 <1% 79 $489.54
80162 <1% 68 $472.24
82523 <1% 102 $462.00
82985 <1% 160 $458.11
81240 <1% 66 $456.82
83718 <1% 449 $447.08
85004 <1% 154 $443.89
85384 <1% 297 $431.04
81015 <1% 323 $424.16
82164 <1% 215 $406.00
86356 <1% 295 $389.66
80165 <1% 94 $376.23
86036 <1% 386 $343.27
86606 <1% 67 $339.25
82705 <1% 260 $339.16
G0472 Hepatitis c antibody screening, for individual at high risk and other covered indication(s) <1% 26 $337.49
80184 <1% 44 $332.86
85049 <1% 150 $316.05
88311 <1% 27 $313.10
84446 <1% 115 $285.82
82131 <1% 42 $271.22
85597 <1% 69 $258.30
84152 <1% 106 $230.94
G0328 Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous <1% 164 $230.00
85300 <1% 67 $227.36
82681 <1% 14 $223.52
87109 <1% 25 $190.08
86355 <1% 12 $173.58
82656 <1% 79 $169.13
87116 <1% 74 $160.90
80321 <1% 78 $156.52
80349 <1% 480 $149.26
83825 <1% 52 $139.96
82175 <1% 27 $120.34
88164 <1% 339 $117.35
80369 <1% 31 $104.40
82552 <1% 70 $103.28
83930 <1% 39 $99.15
85303 <1% 27 $74.65
87807 <1% 12 $73.72
87631 <1% 118 $61.07
82360 <1% 12 $59.42
86747 <1% 13 $53.44
82530 <1% 28 $50.13
86682 <1% 15 $20.80
86880 <1% 27 $16.53
83631 <1% 27 $15.70
86804 <1% 152 $15.18
82955 <1% 12 $8.62
80362 <1% 181 $1.00
87880 Infectious agent antigen detection by immunoassay; Streptococcus, group A 0% 220 $0.00
80339 0% 15 $0.00
86336 0% 224 $0.00
87102 0% 52 $0.00
87905 0% 52 $0.00
84140 0% 12 $0.00
84163 0% 42 $0.00
99284 Emergency room visit (serious) 0% 26 $0.00
93005 Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report 0% 22 $0.00
Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml 0% 12 $0.00
87633 Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets 0% 13 $0.00
36416 0% 270 $0.00
82677 0% 163 $0.00
G0145 Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision 0% 74 $0.00
80345 0% 164 $0.00
80374 0% 98 $0.00
96375 Therapeutic injection; each additional sequential IV push 0% 12 $0.00
81229 0% 14 $0.00
83789 0% 12 $0.00
96374 Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance 0% 12 $0.00
86226 0% 12 $0.00
87593 0% 18 $0.00
87581 0% 26 $0.00
82642 0% 13 $0.00
87486 0% 25 $0.00
84591 0% 26 $0.00
99285 Emergency room visit (most serious) 0% 17 $0.00
99283 Emergency room visit (moderate) 0% 30 $0.00
83874 0% 12 $0.00
83605 0% 12 $0.00
80320 0% 16 $0.00
86738 0% 14 $0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialWILLIAMS, KIMBERLY (VICE PRESIDENT)
Same official

Other billing entities under WILLIAMS, KIMBERLY

Full network →
ProviderLocationPaid
Laboratory Corporation of America HoldingsBurlington, NC$1.44B
Laboratory Corporation of America HoldingsRaritan, NJ$717.47M
Laboratory Corporation of America HoldingsDublin, OH$617.02M
Laboratory Corporation of America HoldingsBirmingham, AL$289.12M
Laboratory Corporation of AmericaPhoenix, AZ$265.90M
Laboratory Corporation of America HoldingsBurlington, NC$264.26M
Laboratory Corporation of America HoldingsCharleston, WV$220.04M
Laboratory Corporation of AmericaSeattle, WA$186.69M
Laboratory Corporation of AmericaTampa, FL$171.13M
Laboratory Corporation of AmericaSan Diego, CA$147.14M
Laboratory Corporation of AmericaHouston, TX$103.81M
Laboratory Corporation of AmericaEnglewood, CO$77.80M
Laboratory Corporation of AmericaDallas, TX$77.42M
Medtox Laboratories, INCSaint Paul, MN$47.72M
Laboratory Corporation of America HoldingsBurlington, NC$15.65M
Laboratory Corporation of AmericaSan Antonio, TX$11.67M
Tri-Cities Laboratory, LLCKennewick, WA$8.69M
Laboratory Corporation of America HoldingsMonroe, LA$3.39M
Laboratory Corporation of AmericaItasca, IL$3.37M
Laboratory Corporation of AmericaAlbany, NY$2.06M

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.